# Petmed Express Inc: Form 10-Q for the period ended Dec 31, 2022

- Company: [Petmed Express Inc](/companies/pets.md) (CIK 1040130)
- Form: 10-Q
- Filed: 2023-02-07
- Accepted by EDGAR: Feb 7, 2023, 17:26 ET
- Period: 2022-12-31
- Accession: 0001040130-23-000013
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1040130/000104013023000013/pets-20221231.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1040130/000104013023000013/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Cost of revenue | 3 months, 2022-10-01 to 2022-12-31 | $43.6m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2022-04-01 to 2022-12-31 | $140.8m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2022-10-01 to 2022-12-31 | $15.2m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2022-04-01 to 2022-12-31 | $53.6m | us-gaap:GrossProfit |
| Operating income | 3 months, 2022-10-01 to 2022-12-31 | −$769.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2022-04-01 to 2022-12-31 | $5.7m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2022-10-01 to 2022-12-31 | $217.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2022-04-01 to 2022-12-31 | $2.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2022-10-01 to 2022-12-31 | −$19.0k | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2022-04-01 to 2022-12-31 | $5.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2022-10-01 to 2022-12-31 | $0.00 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2022-04-01 to 2022-12-31 | $0.26 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2022-10-01 to 2022-12-31 | $0.00 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2022-04-01 to 2022-12-31 | $0.26 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2022-10-01 to 2022-12-31 | 20,301,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2022-04-01 to 2022-12-31 | 20,339,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2022-04-01 to 2022-12-31 | $18.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2022-04-01 to 2022-12-31 | $3.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2022-04-01 to 2022-12-31 | $18.4m | us-gaap:PaymentsOfDividendsCommonStock |
| Cash and equivalents | at 2022-12-31 | $102.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-12-31 | $134.0m | us-gaap:AssetsCurrent |
| Total assets | at 2022-12-31 | $165.1m | us-gaap:Assets |
| Current liabilities | at 2022-12-31 | $31.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-12-31 | $31.5m | us-gaap:Liabilities |
| Shareholders' equity | at 2022-12-31 | $133.6m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 33,266 characters.

The following discussion and analysis should be read in conjunction with our unaudited condensed consolidated financial statements and the related notes thereto included elsewhere in this Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2022 and our Annual Report on Form 10-K for the year ended March 31, 2022.

Certain information in this Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You can identify these forward-looking statements by the words "believes," "intends," "expects," "may," "will," "should," "plans," "projects," "contemplates," "intends," "budgets," "predicts," "estimates," "anticipates," or similar expressions. These statements are based on our beliefs, as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties, and assumptions. Actual future results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such differences include, but are not limited to, those discussed in Part I, Item 1A of our Annual Report on Form 10-K for the year ended March 31, 2022 under the heading “Risk Factors.” A reader, whether investing in our common stock or not, should not place undue reliance on these forward-looking statements, which apply only as of the date of this Quarterly Report on Form 10-Q. We assume no obligation to revise or update any forward-looking statements for any reason, except as required by law.

When used in this Quarterly Report on Form 10-Q, "PetMed Express," "1-800-PetMeds," "PetMeds," "PetMed," "PetMeds.com," “1800PetMeds.com,” "PetMed.com," "PetMed Express.com," "the Company," "we," "our," and "us" refers to PetMed Express, Inc. and our subsidiaries.

### Executive Summary

PetMed Express was incorporated in the state of Florida in January 1996. Our common stock is traded on the NASDAQ Global Select Market under the symbol “PETS”. We began selling pet medications and other pet health products in September 1996. In March 2010 we started offering for sale additional pet supplies on our website, and these additional items are drop shipped to customers by third party vendors. Presently, our product line includes approximately 4,350 SKUs of the most popular pet medications, health products, and supplies for dogs, cats, and horses.

We market our products through advertising and promotional campaigns which aim to increase the recognition of the “PetMeds®” brand name, increase traffic on our website at www.petmeds.com, acquire new customers, and maximize repeat purchases. Approximately 87% of all sales were generated via the Internet for the quarter ended December 31, 2022, compared to 84% for the quarter ended December 31, 2021. Our sales consist of products sold mainly to retail consumers. The average purchase was approximately $90 and $89 for the quarters ended December 31, 2022 and 2021, respectively, and approximately $93 and $92 for the nine months ended December 31, 2022 and 2021, respectively.

### Critical Accounting Policies

Our discussion and analysis of our financial condition and the results of our operations contained herein are based upon our condensed consolidated financial statements and the data used to prepare them. Our condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. On an ongoing basis we re-evaluate our judgments and estimates including those related to product returns, bad debts, inventories, and income taxes. We base our estimates and judgments on our historical experience, knowledge of current conditions, and our beliefs of what could occur in the future considering available information. Actual results may differ from these estimates under different assumptions or conditions. Our estimates are guided by observing the following critical accounting policies.

Revenue recognition

We account for revenue under ASC Topic 606 ("*Revenue from Contracts with Customers")* and generate revenue by selling pet medication products and pet supplies mainly to retail customers. Certain pet supplies offered on our website are drop shipped to customers. We considers ourself the principal in the arrangement because we control the specified good before it is transferred to the customer. Revenue contracts contain one performance obligation, which is delivery of the product; customer care and support is deemed not to be a material right to the contract. The transaction price is adjusted at the date of sale for any applicable sales discounts and an estimate of product returns, which are estimated based on historical patterns, however this is not considered a key judgment. There are no amounts excluded from the variable consideration. Revenue is recognized when control transfers to the customer at the point in time in which the shipment of the product occurs. This key judgment is determined as the shipping point, which represents the point in time where we have a present right to payment, title has transferred to the customer, and the customer has assumed the risks and rewards of ownership.

Outbound shipping and handling fees are an accounting policy election and are included in sales as we considers ourself the principal in the arrangement given responsibility for supplier selection and discretion over pricing. Shipping costs associated with outbound freight after control over a product has transferred to a customer are an accounting policy election and are accounted for as fulfillment costs and are included in cost of sales. Virtually all of our sales are paid by credit cards and we usually receive the cash settlement in two to three banking days. Credit card sales minimize the accounts receivable balances relative to sales.

We maintain an allowance for doubtful accounts for losses that we estimate will arise from customers’ inability to make required payments, arising from either credit card chargebacks or insufficient funds checks. We determine our estimates of the uncollectibility of accounts receivable by analyzing historical and current bad debts and economic trends. The allowance for doubtful accounts was approximately $40 thousand at December 31, 2022, compared to $39 thousand at March 31, 2022.

Valuation of inventory

Inventories consist of prescription and non-prescription pet medications and pet supplies that are available for sale and are priced at the lower of cost or net realizable value using a weighted average cost method. We write down our inventory for estimated obsolescence. The inventory reserve was approximately $56 thousand at December 31, 2022 compared to $81 thousand at March 31, 2022.

Advertising

Our advertising expense consists primarily of Internet marketing, direct mail/print, and television advertising. Internet costs are expensed in the month incurred and direct mail/print advertising costs are expensed when the related brochures and postcards are produced, distributed, or superseded. Television advertising costs are expensed in the month advertisements are televised.

Accounting for income taxes

We account for income taxes under the provisions of ASC Topic 740 (“*Accounting for Income Taxes”*), which generally requires recognition of deferred tax assets and liabilities for the expected future tax benefits or consequences of events that have been included in our condensed consolidated financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting carrying values and the tax bases of assets and liabilities and are measured by applying enacted tax rates and laws for the taxable years in which those differences are expected to reverse.

### Results of Operations

The following should be read in conjunction with our condensed consolidated financial statements and the related notes thereto included elsewhere herein. The following table sets forth, as a percentage of sales, certain operating data appearing in our condensed consolidated statements of income:

|  | Three Months Ended December 31, 2022 | 2021 | Nine Months Ended December 31, 2022 | 2021 |
| --- | ---: | ---: | ---: | ---: |
| Sales | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of sales | 74.1 | 70.8 | 72.4 | 71.7 |
| Gross profit | 25.9 | 29.2 | 27.6 | 28.3 |
| Operating expenses: |  |  |  |  |
| General and administrative | 17.8 | 12.4 | 15.8 | 10.9 |
| Advertising | 7.9 | 7.1 | 7.6 | 7.5 |
| Depreciation | 1.6 | 1.2 | 1.3 | 1.0 |
| Total operating expenses | 27.3 | 20.7 | 24.7 | 19.4 |
| Income (loss) from operations | (1.4) | 8.5 | 2.9 | 8.9 |
| Total other income | 1.6 | 0.6 | 1.0 | 0.5 |
| Income before provision for income taxes | 0.2 | 9.1 | 3.9 | 9.4 |
| Provision for income taxes | 0.4 | 2.1 | 1.2 | 2.2 |
| Net income (loss) | (0.2)% | 7.0% | 2.7% | 7.2% |

### Non-GAAP Financial Measures

#### Adjusted EBITDA

To provide investors and the market with additional information regarding our financial results, we have disclosed (see below) adjusted EBITDA, a non-GAAP financial measure that we calculate as net income excluding share-based compensation expense; depreciation and amortization; income tax provision; interest income (expense); and other non-operational expenses. We have provided reconciliations below of adjusted EBITDA to net income, the most directly comparable GAAP financial measures.

We have included adjusted EBITDA, herein, because it is a key measure used by our management and Board of Directors to evaluate our operating performance, generate future operating plans, and make strategic decisions regarding the allocation of capital. In particular, the exclusion of certain expenses in calculating adjusted EBITDA facilitates operating performance comparability across reporting periods by removing the effect of non-cash expenses and other expenses. Accordingly, we believe that adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and Board of Directors.

We believe it is useful to exclude non-cash charges, such as share-based compensation expense, depreciation and amortization from our adjusted EBITDA because the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations. We believe it is useful to exclude income tax provision and interest income (expense), as neither are components of our core business operations. We also believe that it is useful to exclude other expenses, including the investment banking fee related to the Vetster partnership, acquisition costs related to PetCareRx, employee severance and estimated state sales tax accrual as these items are not indicative of our ongoing operations. Adjusted EBITDA has limitations as a financial measure, and these non-GAAP measures should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:

- Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future and adjusted EBITDA does not reflect capital expenditure requirements for such replacements or for new capital expenditures;
- Adjusted EBITDA does not reflect share-based compensation. Share-based compensation has been, and will continue to be for the foreseeable future, a material recurring expense in our business and an important part of our compensation strategy;
- Adjusted EBITDA does not reflect interest income (expense), net; or changes in, or cash requirements for, our working capital;
- Adjusted EBITDA does not reflect transaction related costs and other items which are either not representative of our underlying operations or are incremental costs that result from an actual or planned transaction and include litigation matters, integration consulting fees, internal salaries and wages (to the extent the individuals are assigned full-time to integration and transformation activities) and certain costs related to integrating and converging IT systems;
- Adjusted EBITDA does not reflect certain non-operating expenses including the employee severance which reduces cash available to us;
- Adjusted EBITDA does not reflect certain expenses including the estimated state sales tax accrual which reduces cash available to us.
- Other companies, including companies in our industry, may calculate adjusted EBITDA differently, which reduces the measures usefulness as comparative measures.

Because of these and other limitations, adjusted EBITDA should only be considered as supplemental to, and alongside with other GAAP based financial performance measures, including various cash flow metrics, net income, net margin, and our other GAAP results.

The following table presents a reconciliation of net income, the most directly comparable GAAP measure to adjusted EBITDA for each of the periods indicated:

### Reconciliation of Non-GAAP Measures

### PetMed Express, Inc.

### (Unaudited)

*($ in thousands, except percentages)*

*Consolidated Reconciliation of GAAP Net Income to Adjusted EBITDA:*

|  | Three Months Ended December 31, 2022 | December 31, 2021 | $ Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Net income (loss) | $(19) | $4,257 | $(4,276) | (100)% |
| Add (subtract): |  |  |  |  |
| Share-based Compensation | 1,770 | 1,440 | 330 | 23% |
| Income Taxes | 217 | 1,261 | (1,044) | (83)% |
| Depreciation | 941 | 710 | 231 | 33% |
| Interest (Income)/Expense | (708) | (84) | (624) | 743% |
| Acquisition and Partnership Transactions | 539 | — | 539 | n/m |
| Employee Severance | — | — | — | n/m |
| State Sales Accrual | — | — | — | n/m |
| Adjusted EBITDA | $2,740 | $7,584 | $(4,844) | (64)% |

*($ in thousands, except percentages)*

*Consolidated Reconciliation of GAAP Net Income to Adjusted EBITDA:*

|  | Nine Months Ended December 31, 2022 | December 31, 2021 | $ Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Net income | $5,335 | $15,034 | $(9,699) | (65)% |
| Add (subtract): |  |  |  |  |
| Share-based Compensation | 4,987 | 3,040 | 1,947 | 64% |
| Income Taxes | 2,278 | 4,603 | (2,325) | (51)% |
| Depreciation | 2,552 | 2,051 | 501 | 24% |
| Interest (Income)/Expense | (1,213) | (243) | (970) | 399% |
| Acquisition and Partnership Transactions | 894 | — | 894 | n/m |
| Employee Severance | 364 | — | 364 | n/m |
| State Sales Accrual | 925 | — | 925 | n/m |
| Adjusted EBITDA | $16,122 | $24,485 | $(8,363) | (34)% |

15

**Three Months Ended December 31, 2022 Compared With Three Months Ended December 31, 2021 and Nine Months Ended December 31, 2022 Compared With Nine Months Ended December 31, 2021**

### COVID-19

We are dedicated to making every effort to ensure our customers’ pets receive the medications they need. We are also dedicated to making every effort to ensure the health and safety of our employees. We have continued with working from home where possible and enhanced disinfection and social distancing within our workplace. We have been open during our normal business hours without any material disruptions to our operations. We have not seen any major disruptions in our supply chain; however, we have experienced some delays in the delivery of some inventory items. The COVID-19 pandemic or any future surges, including as a result of new variants and subvariants of the virus, may have adverse effects on our business, operations, and financial results and condition, including, among other things, as a result of adverse impacts on labor availability, our fulfillment center operations, supply chain and logistics disruptions, consumer behaviors, and on the overall economy, including recent high inflation levels impacting consumer spending. While most areas of the United States have reduced most or all COVID-19 restrictions, as the pandemic continues and if new outbreaks emerge, there is uncertainty regarding the magnitude and duration of the economic and social effects of the COVID-19 pandemic, and therefore, we cannot predict the COVID-19 pandemic full extent of impact on the broader economy or the positive or negative impacts the pandemic will have on our business, operations, and financial results and condition in future periods. See risk factors “*The recent outbreak of the COVID-19 global pandemic and related government, private sector and individual consumer responsive actions may adversely affect our business operations, employee availability, financial performance, liquidity and cash flow for an unknown period of time”* and “*Shipping is a critical part of our business and any changes in, or disruptions to, our shipping arrangements could adversely affect our business, financial condition, and results of operations“* in Part I, Item 1A of our Form 10-K for the year ended March 31, 2022 for further discussion regarding risks associated with the COVID-19 pandemic.

### Sales

Sales decreased by approximately $1.8 million, or 3.0%, to approximately $58.9 million for the quarter ended December 31, 2022, compared to approximately $60.7 million for the quarter ended December 31, 2021. The decrease in sales for the three months ended December 31, 2022 was mainly due to higher seasonal discounts and competitive pressures.

Sales decreased by approximately $13.0 million, or 6.3%, to approximately $194.5 million for the nine months ended December 31, 2022, compared to approximately $207.4 million for the nine months ended December 31, 2021. The decrease in sales for the nine months ended December 31, 2022 was mainly due to the increased cost to acquire new customers and competitive pressures.

We acquired approximately 72,000 new customers for the quarter ended December 31, 2022 compared to approximately 66,000 new customers for the quarter ended December 31, 2021. We acquired approximately 202,000 new customers for the nine months ended December 31, 2022, compared to approximately 260,000 new customers for the nine months ended December 31, 2021. Financial data in the tables below reflects the new 36-month definition of new customers. Prior year new and reorder customers and sales have been recalculated utilizing the new 36-month definition of a new customer (described below). The following tables illustrates sales by various sales classifications:

|  | Three Months Ended December 31, |  |  |  |
| --- | ---: | ---: | ---: | ---: |
| **Revenue (In thousands)** | **2022%** | **2021%** | **$ Variance** | **% Variance** |
| Reorder sales | $53,316 90.6% | $55,259 91.0% | $(1,943) | (3.5)% |
| New order sales | 5,554 9.4% | 5,458 9.0% | 96 | 1.8% |
| Total net sales | $58,870 100.0% | $60,717 100.0% | $(1,847) | (3.0)% |
| Internet sales | $51,109 86.8% | $51,305 84.5% | $(196) | (0.4)% |
| Contact center sales | 7,761 13.2% | 9,412 15.5% | (1,651) | (17.5)% |
| Total net sales | $58,870 100.0% | $60,717 100.0% | $(1,847) | (3.0)% |

16

|  | Nine Months Ended December 31, |  |  |  |
| --- | ---: | ---: | ---: | ---: |
| **Revenue (In thousands)** | **2022%** | **2021%** | **$ Variance** | **% Variance** |
| Reorder sales | $176,384 90.7% | $184,607 89.0% | $(8,223) | (4.5)% |
| New order sales | 18,067 9.3% | 22,808 11.0% | (4,741) | (20.8)% |
| Total net sales | $194,451 100.0% | $207,415 100.0% | $(12,964) | (6.3)% |
| Internet sales | $167,952 86.4% | $173,713 83.8% | $(5,761) | (3.3)% |
| Contact center sales | 26,499 13.6% | 33,702 16.2% | (7,203) | (21.4)% |
| Total net sales | $194,451 100.0% | $207,415 100.0% | $(12,964) | (6.3)% |

Please note that we changed the definition of a new customer on April 1, 2022, to include anyone who has not ordered over the past thirty-six months. The reorder and new order sales amounts for three and nine months ended December 31, 2022 and reorder and new order sales for the three and nine months ended December 31, 2021 reflect this new customer definition change.

Under the previous definition of a new customer, reorder and new order sales were $56.3 million and $4.4 million, respectively, and acquired new customers were approximately 53,000, for the three months ended December 31, 2021. Under the previous definition of a new customer, reorder and new order sales were $189.3 million and $18.2 million, respectively, and acquired new customers were approximately 210,000, for the nine months ended December 31, 2021.

In July 2021 we launched the new AutoShip & Save subscription program (“AutoShip”) on our website. AutoShip is a new convenient way for our loyal customer base to have future pet medication orders delivered directly to them without the need to place an order each time. During the quarter ended June 30, 2022 we made a change to the methodology on how we calculate the percentage of our revenue that was generated by our AutoShip program. We now report AutoShip sales, as a percent of sales, net of discounts and credits for the entire quarter. Previously, we reported AutoShip sales as a percent of total sales on the last month in the quarter. This change to the calculation resulted in a decrease to the AutoShip percentage that was previously reported by only a few percentage points. We believe that this change reflects a more accurate representation of our subscription business for stakeholders to gauge our performance.

We are encouraged by the adoption of our AutoShip program and have seen an increasingly positive trend over the last several quarters since we launched this program. For example, our quarterly AutoShip percentage was 42% of net sales for the most recent quarter ended December 31, 2022, up from 20% of net sales for the same period last year and up from 39% of net sales sequentially in the prior quarter. We have set a goal of generating approximately 50% of our net sales via the AutoShip program in fiscal 2023.

Going forward sales may be adversely affected due to increased competition and consumers giving more consideration to price. The changes in consumer behavior post pandemic makes future sales somewhat challenging to predict. No guarantees can be made that sales will grow in the future. The majority of our product sales are affected by the seasons, due to the seasonality of mainly flea and tick and heartworm medications. For the quarters ended June 30, September 30, December 31, and March 31 of fiscal 2022, our sales were approximately 29%, 25%, 22%, and 24%, respectively, as a percentage of annual sales.

### Cost of sales

Cost of sales increased by approximately $0.6 million, or 1.5%, to approximately $43.6 million for the quarter ended December 31, 2022, from approximately $43.0 million for the quarter ended December 31, 2021. The cost of sales increase was due to changes in accrual from our rewards program of $0.5 million and higher freight expense, partially offset by the impact from lower sales. As a percentage of sales, cost of sales was 74.1% and 70.8% for the quarters ended December 31, 2022 and 2021, respectively.

For the nine months ended December 31, 2022, cost of sales decreased by approximately $7.9 million, or 5.3%, to approximately $140.8 million for the nine months ended December 31, 2022, from approximately $148.7 million for the nine months ended December 31, 2021. The cost of sales decrease can be directly related to the decrease in sales during nine months ended December 31, 2022. As a percentage of sales, cost of sales was 72.4% and 71.7% for the nine months ended December 31, 2022 and 2021, respectively.

### Gross profit

Gross profit decreased by approximately $2.5 million, or 14.0%, to approximately $15.2 million for the quarter ended December 31, 2022, from approximately $17.7 million for the quarter ended December 31, 2021. Gross profit as a percentage of sales was 25.9% and 29.2% for the quarters ended December 31, 2022 and 2021, respectively. The gross profit and gross profit percentage decrease for the quarter ended December 31, 2022 compared to previous period was primarily due to higher promotions and changes in our rewards program accrual.

For the nine months ended December 31, 2022 gross profit decreased by approximately $5.0 million, or 8.6%, to approximately $53.6 million for the nine months ended December 31, 2022, from approximately $58.7 million for the nine months ended December 31, 2021. Gross profit as a percentage of sales for the nine months ended December 31, 2022 and 2021, respectively, was 27.6% and 28.3%. The gross profit and gross profit percentage decreased for the nine months ended December 31, 2022 compared to the previous period was primarily due to lower manufacturer rebates .

### General and administrative expenses

General and administrative expenses increased by approximately $2.9 million, or 38.2%, to approximately $10.4 million for the quarter ended December 31, 2022, from approximately $7.5 million for the quarter ended December 31, 2021. The increase to general and administrative expenses for the quarter ended December 31, 2022 was due to a $1.8 million increase in purposeful investments in people and systems, of which $0.3 million is from increased stock compensation, and an additional $1.0 million of professional fees of which $0.5 million were transaction related expenses.

For the nine months ended December 31, 2022 general and administrative expenses increased by approximately $8.0 million, or 35.4%, to approximately $30.5 million for the nine months ended December 31, 2022, from approximately $22.5 million for the nine months ended December 31, 2021. The increase to general and administrative expenses for the the nine months ended December 31, 2022 was due to a $4.5 million increase in payroll expenses, of which $1.9 million is from increased stock compensation and $0.4M from accrued severance, as well as a $1.0 million increase of professional fees, and $0.7 million of software and systems investment. In addition, general and administrative expenses increased in the nine months ended December 31, 2022 due to a $0.9 million sales tax accrual and $0.9 million of acquisition related expenses.

### Advertising expenses

Advertising expenses increased by approximately $0.3 million, or 7.3%, to approximately $4.6 million for the quarter ended December 31, 2022, from approximately $4.3 million for the quarter ended December 31, 2021. Overall advertising spending for the quarter increased compared to the same quarter the prior year, due to increased media costs and increased agency fees. The advertising costs of acquiring a new customer, defined as total advertising costs divided by new customers acquired, was $64 for the quarter ended December 31, 2022 compared to $66 for the quarter ended December 31, 2021, per the new definition of new customers. The decrease in advertising costs of acquiring a new customer for the quarter ended December 31, 2022 can be mainly attributed to increased conversion due to higher promotions. As a percentage of sales, advertising expense was 7.9% and 7.1% for the quarters ended December 31, 2022 and 2021, respectively. The advertising percentage will fluctuate quarter to quarter due to seasonality and advertising availability.

For the nine months ended December 31, 2022 advertising expenses decreased by approximately $0.6 million, or 3.7%, to approximately $14.9 million for the nine months ended December 31, 2022, from approximately $15.4 million for the nine months ended December 31, 2021. The decrease was primarily due to lower media spend compared to the same period in the prior year. The advertising costs of acquiring a new customer was $74 and $59 for the nine months ended December 31, 2022 and 2021, respectively. The increase in advertising costs of acquiring a new customer for the period can be mainly attributed to increased media costs and competitive pressures. As a percentage of sales, advertising expense was relatively flat, at 7.6% and 7.5% for the nine months ended December 31, 2022 and 2021, respectively.

### Depreciation

Depreciation expense was $0.9 million and $0.7 million for the quarters ended December 31, 2022 and December 31, 2021, respectively. Depreciation expense was $2.6 million and $2.1 million for the nine months ended December 31, 2022 and 2021, respectively. This increase to depreciation expense for the the quarter and nine months ended December 31, 2022 can be attributed to new property and equipment additions subsequent to the prior period.

### Other income

Other income increased to approximately $1.0 million for the quarter ended December 31, 2022 compared to approximately $0.4 million for the quarter ended December 31, 2021. Other income increased to approximately $1.9 million for the nine months ended December 31, 2022 compared to approximately $1.0 million for the nine months ended December 31, 2021. The increase to other income for the quarter and nine months was primarily related to increased interest income as a result of increased interest rates. Interest income may decrease in the future as we utilize our cash balances on any quarterly dividend payment, on future investments or partnerships, on our operating activities, or on our share repurchase plan, which has approximately $28.7 million remaining as of December 31, 2022.

### Provision for income taxes

For the quarters ended December 31, 2022 and 2021, the Company recorded an income tax provision of approximately $0.2 million and $1.3 million, respectively, and for the nine months ended December 31, 2022 and 2021 the Company recorded an income tax provision of approximately $2.3 million and $4.6 million, respectively. The decrease in the tax provision for the three and nine months ended December 31, 2022 is related to a decrease in operating income during the periods. The effective tax rate for the quarter ended December 31, 2022 was approximately 109.6%, compared to approximately 22.9% for the quarter ended December 31, 2021, and the effective tax rate for the nine months ended December 31, 2022 was approximately 29.9% compared to approximately 23.4% for the nine months ended December 31, 2021. The increase to the effective tax rate for the three and nine months ended December 31, 2022 can be attributed to more non-deductible expenses and an increase in state tax due to the extension of the Company's business operations.

### Liquidity and Capital Resources

Our working capital at December 31, 2022 and March 31, 2022 was $102.9 million and $117.8 million, respectively. The $14.9 million decrease in working capital was primarily attributable to a decrease in cash to fund the Vetster partnership and infrastructure investment, and $5 million ownership investment in Vetster. Net cash provided by operating activities was $18.1 million for the nine months ended December 31, 2022, compared to cash provided by operating activities of $9.8 million for the nine months ended December 31, 2021. This change is due to a greater reduction in accounts payable and inventory in the nine months ended December 31, 2022 than in the same period the prior year, partially offset by a decrease to net income. Net cash used in investing activities was $8.3 million for the nine months ended December 31, 2022, compared to $1.3 million used in investing activities for the nine months ended December 31, 2021. This change in investing activities is related to the Vetster partnership and investment, and increased property and equipment additions acquired in the nine months ended December 31, 2022. Net cash used in financing activities was $18.4 million for the nine months ended December 31, 2022 compared to $18.3 million for the nine months ended December 31, 2021, due to the declaration of an aggregate of $0.90 and $0.90 per share dividend during the nine months ended December 31, 2022 and 2021, respectively.

As of December 31, 2022, we had approximately $28.7 million remaining under our share repurchase plan. On February 6, 2023 our Board of Directors declared a $0.30 per share dividend. The Board of Directors established a February 20, 2023 record date and a February 27, 2023 payment date for the quarterly dividend. Depending on future market conditions we may utilize our cash and cash equivalents on quarterly dividends, on our operating activities, or on the remaining balance of our current share repurchase plan.

As of December 31, 2022, we had no material outstanding lease commitments. We are not currently bound by any long- or short-term agreements for the purchase or lease of capital expenditures. Any material amounts expended for capital expenditures would be the result of an increase in the capacity needed to adequately provide for any increase in our business. To date we have paid for any needed additions to our capital equipment infrastructure from working capital funds and anticipate this being the case in the future. Our primary source of working capital is cash from operations. We presently have no need for alternative sources of working capital and have no commitments.

## Market risk

As filed, 1,589 characters.

Market risk generally represents the risk that losses may occur in the value of financial instruments as a result of movements in interest rates, foreign currency exchange rates, and commodity prices. Our financial instruments include cash and cash equivalents, accounts receivable, and accounts payable. The book values of cash equivalents, accounts receivable, and accounts payable are considered to be representative of fair value because of the short maturity of these instruments. Interest rates affect our return on excess cash and cash equivalents. At December 31, 2022, we had $102.4 million in cash and cash equivalents, and the majority of our cash and cash equivalents generate interest income based on prevailing interest rates. A significant change in interest rates would impact the amount of interest income generated from our excess cash and cash equivalents. It would also impact the market value of our cash and cash equivalents. Our cash and cash equivalents are subject to market risk, primarily interest rate and credit risk. Our cash and cash equivalents are managed by a limited number of outside professional managers within investment guidelines set by our Board of Directors. Such guidelines include security type, credit quality, and maturity, and are intended to limit market risk by restricting our cash and cash equivalents to high-quality cash and cash equivalents with both short- and long-term maturities. We do not hold any derivative financial instruments that could expose us to significant market risk. At December 31, 2022, we had no debt obligations.

## Controls and procedures

As filed, 1,586 characters.

### Evaluation of Disclosure Controls and Procedures

Our management, including our Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial and accounting officer), has conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a‑15 and 15d-15 promulgated under the Securities Exchange Act of 1934, as amended ("Exchange Act"), as of the quarter ended December 31, 2022, the end of the period covered by this report (the "Evaluation Date"). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded as of the Evaluation Date, that our disclosure controls and procedures are effective such that the information relating to us, including our consolidated subsidiaries, required to be disclosed by us in reports that we file or submit under the Exchange Act: (1) is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission rules and forms, and (2) is accumulated and communicated to our management, including our principal executive officer and principal financial and accounting officer, as appropriate, to allow timely decisions regarding required disclosure.

### Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 3,207 characters.

Our operations and financial results are subject to various risks and uncertainties that could adversely affect our business, financial condition, results of operations, and trading price of our common stock. Please refer to our Annual Report on Form 10-K for the fiscal year ended March 31, 2022 for additional information concerning these and other uncertainties that could negatively impact the Company.

#### Additional risk factor disclosure

***Taxing authorities may successfully assert that we should have collected, or in the future should collect, sales and use, value added, or similar taxes, and any such assessments could adversely affect our business, financial condition, and results of operations.***

In the past several years states have adopted laws that attempt to impose tax collection obligations on out-of-state companies. Additionally, the Supreme Court of the United States ("Supreme Court") ruled in South Dakota v. Wayfair, Inc. et al, or Wayfair, that online sellers can be required to collect sales and use tax despite not having a physical presence in the buyer’s state. In response to Wayfair, or otherwise, states or local governments may adopt, or begin to enforce, laws requiring us to calculate, collect, and remit taxes on sales in their jurisdictions. While we currently collect and remit applicable sales taxes to the extent required in all states in which we sell, a successful assertion by one or more states seeing to tax us on sales that occurred in prior tax years, or to collect more taxes in a jurisdiction in which we currently do collect some taxes, could result in substantial tax liabilities, including taxes on past sales, as well as penalties and interest. The imposition by state governments or local governments of sales tax collection obligations on out-of-state sellers could also create additional administrative burdens for us, put us at a competitive disadvantage if they do not impose similar obligations on our competitors, and decrease our future sales, which could have a material adverse effect on our business and results of operations. New legislation or regulations, the application of laws and regulations from jurisdictions, or the application of existing laws and regulations to the Internet and commercial online services could similarly result in significant additional taxes on our business. For instance, the Supreme Court’s decision and the enactment and enforcement of laws resulting therefrom could also impact where we are required to file state income taxes. As a result, our effective income tax rate as well as the cost and growth of our business could be materially and adversely affected, which could in turn have a material adverse effect on our financial condition and results of operations. In addition, because the Company’s products and services are available over the Internet, states may claim that the Company is required to do business as a foreign corporation in one or more of those jurisdictions. Failure to qualify as a foreign corporation in a jurisdiction where the Company is required to do so could subject it to taxes and penalties, and such jurisdictions may charge the Company with violations of local laws.

Filed Feb 7, 2023.
Source: SEC EDGAR, the filing index for accession 0001040130-23-000013. Last ingested by Listed: Nov 13, 2026, 14:26 ET. No prices; not investment advice.
